Aerie Pharmaceuticals v. Gland Pharma: Netarsudil Patent Dispute Transferred in NJ ANDA Litigation
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Aerie Pharmaceuticals, Inc. v. Gland Pharma, Ltd. |
| Case Number | 3:22-cv-01359 (transferred to 1:22-cv-1359) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Mar 2022 – Mar 2024 2 years 0 months 14 days |
| Outcome | Transferred — Litigation Continues |
| Patents at Issue | |
| Accused Products | Netarsudil mesylate ophthalmic solution equivalent to 0.02% base (generic Rhopressa®) |
Case Overview
The Parties
⚖️ Plaintiff
A specialty pharmaceutical company focused on ophthalmic therapies, holding a robust patent portfolio surrounding netarsudil (Rhopressa®).
🛡️ Defendant
An India-headquartered injectable and ophthalmic pharmaceutical manufacturer with significant generic drug operations.
Patents at Issue
This litigation involved four U.S. patents protecting different aspects of Aerie’s netarsudil formulation and its therapeutic applications, crucial for its branded product, Rhopressa®.
- • US9931336B2 — Covering netarsudil formulations
- • US9415043B2 — Covering earlier composition and method claims
- • US11185538B2 — A more recently issued patent in the netarsudil family
- • US10588901B2 — Covering additional therapeutic use or formulation aspects
Developing a netarsudil-adjacent product?
Assess if your ophthalmic formulation might infringe these or related patents before commercialization.
The Verdict & Legal Analysis
Outcome
The case was **transferred** on March 28, 2024, from the Newark Division to the Camden Division of the U.S. District Court for the District of New Jersey, receiving the new case designation **1:22-cv-1359**. This procedural outcome means the litigation is ongoing, and no merits ruling, damages award, or injunctive relief order has been issued as of this analysis.
Key Legal Issues
The core legal issues in this case revolve around a classic Paragraph IV ANDA certification under the Hatch-Waxman Act: whether Gland Pharma’s proposed generic netarsudil mesylate ophthalmic solution infringes Aerie’s four patents, and whether those patents are valid and enforceable. The simultaneous assertion of multiple patents creates complex claim construction and validity challenges for both parties.
For patent attorneys, the procedural transfer highlights docket management practices within multi-divisional federal courts and emphasizes that jurisdictional shifts do not equate to case resolution.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in ophthalmic pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the netarsudil technology space
- See which companies are most active in ophthalmic IP
- Understand claim construction patterns for ROCK inhibitors
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your pharmaceutical formulation or therapeutic method
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Netarsudil formulations and methods of use
4 Patents Asserted
Across composition, formulation, and method
Prior Art Search
Essential for ANDA challenges
✅ Key Takeaways
Multi-patent ANDA assertions necessitate coordinated claim construction and validity strategy across related patent families.
Search related case law →Intra-district transfers (like from Newark to Camden) are procedural and do not resolve substantive claims; monitoring the successor docket is crucial.
Explore court dockets →Continuation patent portfolios, especially for pharmaceutical innovations, remain a powerful tool for extending and layering IP protection.
Analyze patent families →Frequently Asked Questions
Four U.S. patents were asserted: US9931336B2, US9415043B2, US11185538B2, and US10588901B2 — all relating to netarsudil mesylate ophthalmic formulations.
The case was administratively transferred from the Newark Division to the Camden Division of the New Jersey District Court on March 28, 2024, for docket management purposes. The substantive infringement claims continue under Case No. 1:22-cv-1359.
Claim construction rulings in the transferred proceeding could define the scope of Aerie’s netarsudil patents broadly, affecting other generic manufacturers pursuing ANDA approvals for netarsudil-based products.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- New Jersey District Court PACER Docket — Case No. 3:22-cv-01359
- USPTO Patent Center — Patent Information
- USPTO Patent Trial and Appeal Board (PTAB)
- Cornell Legal Information Institute — 35 U.S.C. § 271 (Hatch-Waxman Act)
- U.S. Food & Drug Administration (FDA) — Generic Drug Program
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.